Archives20242023202220212020201920182017201620152014201320122011 September 11, 2020Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients Read More September 10, 2020Conversion of Convertible Security – Lind Global Macro Fund, LP Read More September 09, 2020Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund Read More September 08, 2020TR1 – Notification of major interest in shares by Lanstead Capital Read More September 08, 2020Director/PDMR Shareholding/TR-1 Read More September 07, 2020Placing to raise £6.5 million – update; related party transaction Read More September 03, 2020Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund Read More September 02, 2020Placing to raise £6.5 million Read More September 01, 2020TR1 – Notification of major interest in shares by Lanstead Capital Read More July 27, 2020Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients Read More June 18, 20202020 Annual General Meeting – all Resolutions Passed Read More June 16, 2020Total Share Capital Notification Read More 1234
September 11, 2020Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients Read More
September 09, 2020Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund Read More
September 03, 2020Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund Read More
July 27, 2020Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients Read More
